Technology ID
TAB-4867
Advancements in Coronavirus Vaccine Development: Innovative Engineered RBD Antigens Redefining the Landscape
E-Numbers
E-045-2021-0
Lead Inventor
Tolia, Niraj
Lead IC
NIAID
Co-Inventors
Dickey, Thayne
ICs
NIAID
Applications
Vaccines
Therapeutic Areas
Infectious Disease
Development Stages
Pre-Clinical (in vitro)
Research Products
Computational models/software
Antibodies
Novel Engineered RBD Antigens: Elevating Coronavirus Vaccine Efficiency and Efficacy. These groundbreaking antigens, derived from the spike protein's receptor-binding domain, are meticulously designed through a computational pipeline, resulting in superior attributes. They increase protein yield sevenfold, ensuring efficient large-scale manufacturing. With elevated thermal stability and a tenfold boost in antibody production, these antigens present a significant stride towards potent and globally accessible coronavirus vaccines.
Commercial Applications
This technology has diverse potential applications. Beyond coronavirus vaccines, its engineered RBD antigens can serve as a platform for vaccines against other viruses and be valuable for long-term storage in resource-limited areas. They may also enhance diagnostic assays. Furthermore, the computational protein design pipeline could have applications in various biotechnological and pharmaceutical fields.
Competitive Advantages
This technology provides a competitive edge in coronavirus vaccine development. Engineered RBD antigens, designed computationally, offer sevenfold production efficiency, superior thermal stability, and tenfold increased antibody production, potentially leading to more potent vaccines and cost-effective large-scale manufacturing.
Licensing Contact: